Adverse events during treatment of drug-resistant tuberculosis: A comparison between patients with or without human immunodeficiency virus co-infection

Drug Safety

Volumn 36, Issue 11, 2013, Pages 1087-1096

  Sagwa, Evans ^a,b,c,f   Ruswa, Nunurai ^d   Musasa, Jean Paul ^e   Mantel Teeuwisse, Aukje K ^b  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Management Sciences for Health   (Namibia)

^d National Tuberculosis and Leprosy Programme   (Namibia)

^e Ministry of Health and Social Services   (Namibia)

^f NONE   (Namibia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESISTANT TUBERCULOSIS; FATIGUE; FEMALE; GENDER; HEARING IMPAIRMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TINNITUS; TREMOR; VISUAL IMPAIRMENT; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NAMIBIA; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84887188291     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0091-1     Document Type: Article

References (35)

1. Ministry of Health and Social Services (MoHSS). National tuberculosis and leprosy programme: second medium term strategic plan for tuberculosis and leprosy, 2010-2015. Windhoek: MoHSS; 2010.
2. Ministry of Health and Social Services (MoHSS). 2011/12 estimates and projections of the impact of HIV and AIDS in Namibia. Windhoek: MoHSS; 2012.
3. Ministry of Health and Social Services. National tuberculosis and leprosy programme annual report: 2011-2012. MoHSS: Windhoek; 2012.
4. World Health Organization (WHO). Treatment of tuberculosis. 4th ed. WHO/HTM/TB/2009.420. Geneva: WHO; 2010.
5. Ministry of Health and Social Services (MoHSS). National guidelines for the management of tuberculosis. 2nd ed. Windhoek: MoHSS; 2006.
6. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2005;9:1027-33.
7. Törün T, Güngör G, Özmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:1373-7.
8. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11:1314-20.
9. Bloss E, Kukša L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010;14:275-81.
10. Venkatesh KK, Swaminathan S, Andrews JR, et al. Tuberculosis and HIV co-infection: screening and treatment strategies. Drugs. 2011;71(9):1133-52.
11. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One. 2012;7(7):e40781. doi: 10.1371/journal.pone.0040781.
12. Marks DJB, Dheda K, Dawson R, et al. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009;20(5):339-45.
13. Xu W, Lu W, Zhou Y, et al. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res. 2009;9:168.
14. Lorent N, Sebatunzi O, Mukeshimana G, et al. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS One. 2011;6(5):e19566. doi: 10.1371/journal.pone. 0019566.
15. Sagwa E, Mantel-Teeuwisse A, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev. 2012;5(1):6-13.
16. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472-7.
17. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother. 2004 Jun;38(6):1074-9.
18. Pande JN, Singh SPN, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51(2):132-6.
19. Nahar BL, Mosharrof Hossain AKM, Islam MM, et al. A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period. Bangladesh J Pharmacol. 2006;1:51-7.
20. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:648-55.
21. Chhetri AK, Saha A, Verma SC, et al. A study of adverse drug reactions caused by first line anti-tubercular drugs in Directly Observed Treatment, Short Course (DOTS) therapy in western Nepal, Pokhara. J Pak Med Assoc. 2008;58(10):531-6.
22. Kishore PV, Subish P, Pradip O, et al. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in western Nepal. Pak J Pharm Sci. 2008;21(1):51-6.
23. Gholami K, Kamali E, Hajiabdolbaghi M, et al. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract. 2006;4(3):134-8.
24. Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2007;65(3):396-406.
25. Sagwa E. Prevalence and risk factors of adverse events during treatment of drug resistant tuberculosis in a setting of high human immunodeficiency virus co-infection in Namibia: 2009-10. Unpublished Master of Public Health Thesis, Cape Town, South Africa; University of the Western Cape, Feb 2012.
26. Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. Plos One. 2009;4:e7186. doi: 10.1371/journal.pone.0007186.
27. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of multidrug-resistant tuberculosis. CMAJ. 2002;167:131-6.
28. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6:622-7.
29. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7:5. doi: 10.1186/1472-6815-7-5.
30. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:797-800.
31. Nadol JB. Medical progress: hearing loss. N Engl J Med. 1993;329:1092-102.
32. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13:119-26.
33. Sturdy A, Goodman A, Jose RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66:1815-20.
34. Tupasi TE, Gupta R, Quelapio MID, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. Plos One. 2006;3:e352. doi: 10.1371/journal.pmed.0030352.
35. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-30.